Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2024-10-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of wild-type reovirus (pelareorep)
when given together with dexamethasone, carfilzomib, and nivolumab in treating patients with
multiple myeloma that has come back (relapsed). Drugs used in chemotherapy, such as
dexamethasone, work in different ways to stop the growth of cancer cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Carfilzomib
may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune
system attack the cancer and may interfere with the ability of tumor cells to grow and
spread. A virus, called pelareorep, which has been changed in a certain way, may be able to
kill tumor cells without damaging normal cells. Giving dexamethasone, carfilzomib, and
nivolumab with pelareorep may work better in treating patients with multiple myeloma.
Phase:
Phase 1
Details
Lead Sponsor:
Emory University
Collaborators:
Bristol-Myers Squibb City of Hope Medical Center Oncolytics Biotech Phylogeny University of Utah